🔎 Trials Near Me

Hjem › Myelogen leukemi i kronisk fase › California

Kliniske studier for Myelogen leukemi i kronisk fase i California

5 studier for Myelogen leukemi i kronisk fase søker deltakere på steder i California.

Offisiell studietekst (engelsk)

Study of Olverembatinib (HQP1351) in Patients With CML-CP

  • Ascentage Investigative Site #1062, Duarte
  • Ascentage Investigative Site #1099, Irvine
  • Ascentage Investigative Site #1075, La Jolla
  • og 4 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT06423911

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

  • City of Hope Medical Center, Duarte
RekruttererFase 1Frivillige helsepersonell ønskes velkommen
Alder 18 til 75 · Alle kjønn · Oppdatert 28. jul. 2026 · NCT07020533

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

  • Stockton Hematology Oncology Medical Group Inc, Stockton
  • Lundquist Inst BioMed at Harbor, Torrance
RekruttererObservasjonsstudie
Alder 18 til 100 · Alle kjønn · Oppdatert 20. jul. 2026 · NCT07091019

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia

  • Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 10. mar. 2026 · NCT06229860

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

  • UC Irvine Health, Orange
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 12. jan. 2026 · NCT06163430

Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.